Friday, March 29, 2019 9:50:51 AM
Cannabix has lost money every single year since inception (Over $6.7 Million total)
Each year Cannabix adds over 10 Million shares outstanding - diluting current shareholders
There has never been a sale or source of revenue since going public
Money going into R & D has never been over a Million $/year
EPS has always been negative and that will most likely be the case for 2019
Now let's compare to Lifeloc:
Lifeloc has made money every year since inception - (Over $43 Million since 2014)
Lifeloc has had sales/revenue of $8 Million or more every single year since 2014
Lifeloc has over $1 Million/year going into R & D efforts since 2014
Lifeloc has never diluted current shareholders - This is amazing. There are only a handful of companies that can say that.
Lifeloc has has positive EPS every year since becoming a public company
And recall that the preliminary work being done on the SpixDx technology began way before Cannabix even became a public company.
Bottom line - Lifeloc deserves to be valued at minimum to that of BLOZF
$45/Share - First price target.
This side by side comparison should put everything into perspective.
In my personal opinion, after doing this comparison I believe LCTC should trade at a 2-5 x multiple to that of BLOZF.
Let me know your thoughts/opinions on these findings.
Thanks and all the best!
Recent LCTC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:14:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:46:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 02:57:07 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/23/2023 02:57:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 09:11:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 08:21:40 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM